In situ Fourier transform infrared analysis of live cells' response to doxorubicin

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1853, Issue 10, 2015, Pages 2640-2648

  Fale, Pedro L ^a   Altharawi, Ali ^a   Chan, K L Andrew ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Chemotherapy; Drug resistance; Drug screening; Infrared spectroscopy; Living cells; Multi bounce ATR

Indexed keywords

AMIDE; CARBOHYDRATE; DOXORUBICIN; NUCLEIC ACID; ANTINEOPLASTIC ANTIBIOTIC;

ARTICLE; CANCER CELL LINE; CELL VIABILITY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CRYSTAL; FEMALE; HUMAN; HUMAN CELL; INFRARED SPECTROSCOPY; MTT ASSAY; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; CACO 2 CELL LINE; DRUG EFFECTS; DRUG RESISTANCE; HELA CELL LINE;

ANTIBIOTICS, ANTINEOPLASTIC; CACO-2 CELLS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; HELA CELLS; HUMANS; SPECTROSCOPY, FOURIER TRANSFORM INFRARED;

EID: 84938814184     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2015.07.018     Document Type: Article

References (49)

1. Baker M.J., Trevisan J., Bassan P., Bhargava R., Butler H.J., Dorling K.M., Fielden P.R., Fogarty S.W., Fullwood N.J., Heys K.A., Hughes C., Lasch P., Martin-Hirsch P.L., Obinaju B., Sockalingum G.D., Sule-Suso J., Strong R.J., Walsh M.J., Wood B.R., Gardner P., Martin F.L. Using Fourier transform IR spectroscopy to analyze biological materials. Nat. Protoc. 2014, 9(8):1771-1791.
2. Boydston-White S., Chernenko T., Regina A., Miljkovic M., Matthaus C., Diem M. Microspectroscopy of single proliferating HeLa cells. Vib. Spectrosc. 2005, 38(1-2):169-177.
3. Liu K.Z., Jia L., Kelsey S.M., Newland A.C., Mantsch H.H. Quantitative determination of apoptosis on leukemia cells by infrared spectroscopy. Apoptosis 2001, 6(4):269-278.
4. P.U.Otero E., G.da Silva Neto E., J.S.Fonseca E., M.Hickmann J., Rodarte R., Barreto E., J.Jalkanen K. Study of cancer cell lines with Fourier Transform Infrared (FTIR)/Vibrational Absorption (VA) Spectroscopy. Curr. Phys. Chem. 2013, 3(1):36-43.
5. Verdonck M., Wald N., Janssis J., Yan P., Meyer C., Legat A., Speiser D.E., Desmedt C., Larsimont D., Sotiriou C., Goormaghtigh E. Breast cancer and melanoma cell line identification by FTIR imaging after formalin-fixation and paraffin-embedding. Analyst 2013, 138(14):4083-4091.
6. Lewis P.D., Lewis K.E., Ghosal R., Bayliss S., Lloyd A.J., Wills J., Godfrey R., Kloer P., Mur L.A.J. Evaluation of FTIR Spectroscopy as a diagnostic tool for lung cancer using sputum. BMC Cancer 2010, 10.
7. Gaigneaux A., Decaestecker C., Camby I., Mijatovic T., Kiss R., Ruysschaert J.M., Goormaghtigh E. The infrared spectrum of human glioma cells is related to their in vitro and in vivo behavior. Exp. Cell Res. 2004, 297(1):294-301.
8. Berger G., Gasper R., Lamoral-Theys D., Wellner A., Gelbcke M., Gust R., Neve J., Kiss R., Goormaghtigh E., Dufrasne F. Fourier transform infrared (FTIR) spectroscopy to monitor the cellular impact of newly synthesized platinum derivatives. Int. J. Oncol. 2010, 37(3):679-686.
9. Derenne A., Gasper R., Goormaghtigh E. The FTIR spectrum of prostate cancer cells allows the classification of anticancer drugs according to their mode of action. Analyst 2011, 136(6):1134-1141.
10. Draux F., Jeannesson P., Gobinet C., Sule-Suso J., Pijanka J., Sandt C., Dumas P., Manfait M., Sockalingum G.D. IR spectroscopy reveals effect of non-cytotoxic doses of anti-tumour drug on cancer cells. Anal. Bioanal. Chem. 2009, 395(7):2293-2301.
11. Rutter A.V., Siddique M.R., Filik J., Sandt C., Dumas P., Cinque G., Sockalingum G.D., Yang Y., Sule-Suso J. Study of gemcitabine-sensitive/resistant cancer cells by cell cloning and synchrotron FTIR microspectroscopy. Cytometry A 2014, 85(8):688-697.
12. Zendehdel R., Masoudi-Nejad A., Mohammadzadeh J., Shirazi F.H. Cisplatin resistant patterns in ovarian cell line using FTIR and principle component analysis. Iran. J. Pharm. Res. 2012, 11(1):235-240.
13. Zwielly A., Gopas J., Brkic G., Mordechai S. Discrimination between drug-resistant and non-resistant human melanoma cell lines by FTIR spectroscopy. Analyst 2009, 134(2):294-300.
14. Bedolla D.E., Kenig S., Mitri E., Ferraris P., Marcello A., Grenci G., Vaccari L. Determination of cell cycle phases in live B16 melanoma cells using IRMS. Analyst 2013, 138(14):4015-4021.
15. Huang H.L., Hsing H.W., Lai T.C., Chen Y.W., Lee T.R., Chan H.T., Lyu P.C., Wu C.L., Lu Y.C., Lin S.T., Lin C.W., Lai C.H., Chang H.T., Chou H.C., Chan H.L. Trypsin-induced proteome alteration during cell subculture in mammalian cells. J. Biomed. Sci. 2010, 17:36.
16. Yamaguchi R., Hirano-Iwata A., Kimura Y., Niwano M., Miyamoto K., Isoda H., Miyazaki H. In situ real-time monitoring of apoptosis on leukemia cells by surface infrared spectroscopy. J. Appl. Phys. 2009, 105(2).
17. Alam M.K., Timlin J.A., Martin L.E., Williams D., Lyons C.R., Garrison K., Hjelle B. Spectroscopic evaluation of living murine macrophage cells before and after activation using attenuated total reflectance infrared spectroscopy. Vib. Spectrosc. 2004, 34(1):3-11.
18. Timlin J.A., Martin L.E., Lyons C.R., Hjelle B., Alam M.K. Dynamics of cellular activation as revealed by attenuated total reflectance infrared spectroscopy. Vib. Spectrosc. 2009, 50(1):78-85.
19. Aonuma Y., Kondo Y., Hirano-Iwata A., Nishikawa A., Shinohara Y., Iwata H., Kimura Y., Niwano M. Label-free and real time monitoring of adipocyte differentiation by surface infrared spectroscopy. Sensors Actuators B Chem. 2013, 176:1176-1182.
20. Miyamoto K.I., Yamada P., Yamaguchi R.T., Muto T., Hirano A., Kimura Y., Niwano M., Isoda H. In situ observation of a cell adhesion and metabolism using surface infrared spectroscopy. Cytotechnology 2007, 55(2-3):143-149.
21. Schmidt M., Wolfram T., Rumpler M., Tripp C.P., Grunze M. Live cell adhesion assay with attenuated total reflection infrared spectroscopy. Biointerphases 2007, 2(1):1-5.
22. Hutson T.B., Mitchell M.L., Keller J.T., Long D.J., Chang M.J.W. A technique for monitoring mammalian-cell growth and inhibition in situ via fourier-transform infrared-spectroscopy. Anal. Biochem. 1988, 174(2):415-422.
23. Chan K.L., Fale P.L. Label-free in situ quantification of drug in living cells at micromolar levels using infrared spectroscopy. Anal. Chem. 2014, 86(23):11673-11679.
24. Gaigneaux A., Goormaghtigh E. A new dimension for cell identification by FTIR spectroscopy: depth profiling in attenuated total reflection. Analyst 2013, 138(14):4070-4075.
25. Kazarian S.G., Chan K.L.A. ATR-FTIR spectroscopic imaging: recent advances and applications to biological systems. Analyst 2013, 138(7):1940-1951.
26. Veldman R.J., Koning G.A., van Hell A., Zerp S., Vink S.R., Storm G., Verheij M., van Blitterswijk W.J. Coformulated N-octanoyl-glucosylceramide improves cellular delivery and cytotoxicity of liposomal doxorubicin. J. Pharmacol. Exp. Ther. 2005, 315(2):704-710.
27. Leung S.L., Zha Z., Teng W., Cohn C., Dai Z., Wu X. Organic-inorganic nanovesicles for doxorubicin storage and release. Soft Matter 2012, 8(21):5756.
28. Ma W., Wang J., Guo Q., Tu P. Simultaneous determination of doxorubicin and curcumin in rat plasma by LC-MS/MS and its application to pharmacokinetic study. J. Pharm. Biomed. Anal. 2015, 111:215-221.
29. Armbruster C., Vorbach H., Steindl F., El Menyawi I. Intracellular concentration of the HIV protease inhibitors indinavir and saquinavir in human endothelial cells. J. Antimicrob. Chemother. 2001, 47(4):487-490.
30. Czerlinski G.H., Reid D.S., Apostol A., Bauer K.D., Scarpelli D.G. Determination of the density of cells from sedimentation studies at 1G. J. Biol. Phys. 1987, 15(2):29-32.
31. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65(1-2):55-63.
32. Vermeer L.S., Fruhwirth G.O., Pandya P., Ng T., Mason A.J. NMR metabolomics of MTLn3E breast cancer cells identifies a role for CXCR4 in lipid and choline regulation. J. Proteome Res. 2012, 11(5):2996-3003.
33. Kuimova M.K., Chan K.L.A., Kazarian S.G. Chemical imaging of live cancer cells in the natural aqueous environment. Appl. Spectrosc. 2009, 63(2):164-171.
34. Liu Y., Huo Z., Yan B., Lin X., Zhou Z.N., Liang X., Zhu W., Liang D., Li L., Liu Y., Zhao H., Sun Y., Chen Y.H. Prolyl hydroxylase 3 interacts with Bcl-2 to regulate doxorubicin-induced apoptosis in H9c2 cells. Biochem. Biophys. Res. Commun. 2010, 401(2):231-237.
35. Birarda G., Bedolla D.E., Mitri E., Pacor S., Grenci G., Vaccari L. Apoptotic pathways of U937 leukemic monocytes investigated by infrared microspectroscopy and flow cytometry. Analyst 2014, 139(12):3097-3106.
36. Barpe D.R., Rosa D.D., Froehlich P.E. Pharmacokinetic evaluation of doxorubicin plasma levels in normal and overweight patients with breast cancer and simulation of dose adjustment by different indexes of body mass. Eur. J. Pharm. Sci. 2010, 41(3-4):458-463.
37. Biazik J.M., Jahn K.A., Su Y.Y., Wu Y.N., Braet F. Unlocking the ultrastructure of colorectal cancer cells in vitro using selective staining. World J. Gastroenterol. 2010, 16(22):2743-2753.
38. Kakuyama A., Sadzuka Y. Effect of methylxanthine derivatives on doxorubicin transport and antitumor activity. Curr. Drug Metab. 2001, 2(4):379-395.
39. Roepe P.D. Analysis of the steady-state and initial rate of doxorubicin efflux from a series of multidrug resistant cells expressing different levels of P-glycoprotein. Biochemistry 1992, 31(50):12555-12564.
40. Carriere V., Rodolosse A., Lacasa M., Cambier D., Zweibaum A., Rousset M. Hypoxia and CYP1A1 induction-dependent regulation of proteins involved in glucose utilization in Caco-2 cells. Am. J. Physiol. 1998, 274(6 Pt 1):G1101-G1108.
41. Rousset M., Laburthe M., Pinto M., Chevalier G., Rouyer-Fessard C., Dussaulx E., Trugnan G., Boige N., Brun J.L., Zweibaum A. Enterocytic differentiation and glucose utilization in the human colon tumor cell line Caco-2: modulation by forskolin. J. Cell. Physiol. 1985, 123(3):377-385.
42. Thomas M.B., Radhakrishnan K., Gnanadhas D.P., Chakravortty D., Raichur A.M. Intracellular delivery of doxorubicin encapsulated in novel pH-responsive chitosan/heparin nanocapsules. Int. J. Nanomedicine 2013, 8:267-273.
43. David-Beabes G.L., Overman M.J., Petrofski J.A., Campbell P.A., De Marzo A.M., Nelson W.G. Doxorubicin-resistant variants of human prostate cancer cell lines DU 145, PC-3, PPC-1, and TSU-PR1: characterization of biochemical determinants of antineoplastic drug sensitivity. Int. J. Oncol. 2000, 17(6):1077-1086.
44. van der Sandt I.C.J., Blom-Roosemalen M.C.M., de Boer A.G., Breimer D.D. Specificity of doxorubicin versus rhodamine-123 in assessing P-glycoprotein functionality in the LLC-PK1, LLC-PK1: MDR1 and Caco-2 cell lines. Eur. J. Pharm. Sci. 2000, 11(3):207-214.
45. Walsh M.J., Fellous T.G., Hammiche A., Lin W.R., Fullwood N.J., Grude O., Bahrami F., Nicholson J.M., Cotte M., Susini J., Pollock H.M., Brittan M., Martin-Hirsch P.L., Alison M.R., Martin F.L. Fourier transform infrared microspectroscopy identifies symmetric PO(2)(-) modifications as a marker of the putative stem cell region of human intestinal crypts. Stem Cells 2008, 26(1):108-118.
46. Whelan D.R., Bambery K.R., Heraud P., Tobin M.J., Diem M., McNaughton D., Wood B.R. Monitoring the reversible B to A-like transition of DNA in eukaryotic cells using Fourier transform infrared spectroscopy. Nucleic Acids Res. 2011, 39(13):5439-5448.
47. Mahon K.L., Henshall S.M., Sutherland R.L., Horvath L.G. Pathways of chemotherapy resistance in castration-resistant prostate cancer. Endocr. Relat. Cancer 2011, 18(4):R103-R123.
48. Dan H.C., Adli M., Baldwin A.S. Regulation of mammalian target of rapamycin activity in PTEN-inactive prostate cancer cells by I kappa B kinase alpha. Cancer Res. 2007, 67(13):6263-6269.
49. Misra B.C., Srivatsan E.S. Localization of HeLa cell tumor-suppressor gene to the long arm of chromosome II. Am. J. Hum. Genet. 1989, 45(4):565-577.